ESMO 2020

Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients with Platinum-Resistant Ovarian Cancer: The NINJA Trial
ESMO 2020
A phase 3 study comparing nivolumab to treatment with gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer revealed similar overall survival and response rates between the 2 groups. Nivolumab was better tolerated than gemcitabine/pegylated liposomal doxorubicin, with fewer all-grade and grade 3/4 adverse events. Read More ›
Efficacy and Safety of Front-Line Veliparib and Paclitaxel Weekly versus Every 3 Weeks in the VELIA Study
ESMO 2020
In patients with newly diagnosed high-grade serous ovarian cancer, dose-dense weekly paclitaxel was associated with longer progression-free survival and higher frequency of grade 3/4 adverse events, including hematologic toxicities, versus paclitaxel given every 3 weeks. Read More ›
Timing of Adverse Events During Maintenance Treatment with Rucaparib for Recurrent Ovarian Cancer in Phase 3 Study
ESMO 2020
The phase 3 ARIEL3 study investigated rucaparib as maintenance therapy in patients with recurrent ovarian cancer. An exploratory safety analysis found time to onset of nonhematologic treatment-emergent adverse events was 1 month, 2 months for anemia, and 3 months for decreased hemoglobin. Read More ›
Response to Olaparib Monotherapy in Relapsed Ovarian Cancer by HRR Gene Mutational Status and HRD Scarring Analysis
ESMO 2020
A phase 2, randomized study of patients with platinum-resistant relapsed ovarian cancer assessed overall response to olaparib monotherapy compared with standard-of-care chemotherapy. Olaparib was effective in platinum-resistant and platinum-sensitive patients with and without homologous recombination repair (HRR) gene alterations. Read More ›
Olaparib Maintenance Therapy in Clinical Practice: Quality-of-Life Interim Results of the C-PATROL Study in Ovarian Cancer
ESMO 2020
An observational study of hospitalized patients and patients in outpatient treatment facilities being treated with olaparib as maintenance therapy for relapsed BRCA-mutated ovarian cancer following platinum-based chemotherapy reveals preservation of health-related quality of life in interim study results. Read More ›
Efficacy and Safety of Niraparib in Older Patients with Advanced Ovarian Cancer from PRIMA/ENGOT-OV26/GOG-3012
ESMO 2020
In patients with advanced ovarian cancer, niraparib resulted in similar efficacy, safety, and quality-of-life outcomes for patients 65 years of age and those ≥65 years of age. An individualized starting dose resulted in fewer grade ≥3 thrombocytopenia events than a fixed starting dose. Read More ›
Phase 2 Trial of Olvi-Vec in Heavily Pretreated Platinum-Resistant/Refractory Ovarian Cancer
ESMO 2020
The VIRO-15 trial of intraperitoneal Olvi-Vec virus infusion followed by intravenous carboplatin-doublet ± bevacizumab in pretreated platinum-resistant/refractory ovarian cancer patients revealed promising response rates and progression-free survival. Safety results were consistent with a previous phase 1b trial of this agent. Read More ›
Olaparib + Durvalumab and Bevacizumab: Initial Results in Patients with Non-Germline BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer
ESMO 2020
For patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer, the triple combination of olaparib, durvalumab, and bevacizumab demonstrated a promising 24-week disease control rate and safety profile while the combination of olaparib plus durvalumab did not meet the prespecified efficacy target. Read More ›
Results of 5-Year Follow-Up of Maintenance Olaparib in Patients with Newly Diagnosed, Advanced Ovarian Cancer
ESMO 2020
The SOLO1 trial studied maintenance olaparib in newly diagnosed patients with advanced BRCA-mutated ovarian cancer. This analysis assesses outcomes 5 years after the last patient enrolled in the trial and represents the longest follow-up for a PARP inhibitor trial in this setting. Read More ›
Results from the GEICO1601-ROLANDO Phase 2 Trial Evaluating Combination of Olaparib and PLD in Platinum-Resistant Ovarian Cancer
ESMO 2020
In patients with platinum-resistant ovarian cancer, 46% treated per protocol with olaparib and pegylated liposomal doxorubicin (PLD) achieved 6-month progression-free survival regardless of BRCA status. Adverse events were less frequent with a reduction of the PLD dose. Read More ›

Page 1 of 2

  • 1
  • 2

© Amplity Health. All Rights Reserved. Privacy Policy